Contineum Therapeutics, Inc.
CTNM
$14.19
-$1.11-7.26%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -1.22% | -17.28% | -41.93% | -67.47% | -80.82% |
| Total Depreciation and Amortization | 30.27% | 19.27% | 25.19% | 42.27% | 46.27% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 66.79% | 88.25% | 171.71% | 289.40% | 2,568.47% |
| Change in Net Operating Assets | -497.91% | -374.18% | -213.22% | -480.79% | 240.31% |
| Cash from Operations | -14.13% | -45.53% | -68.40% | -57.35% | -42.66% |
| Capital Expenditure | -35.10% | -19.81% | 55.06% | 45.97% | 43.22% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -100.00% | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -536.26% | 9.06% | 94.97% | 168.48% | 82.59% |
| Cash from Investing | -521.67% | 8.84% | 94.68% | 166.94% | 82.23% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 11,961.42% | 3.87% | 3.61% | -81.44% | -99.13% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -14.77% | -332.14% | -- | 25.36% | 48.69% |
| Cash from Financing | 14,692.08% | 3.44% | 3.38% | -81.62% | -99.35% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 89.24% | -137.25% | 736.22% | -92.55% | -324.34% |